From July 8–10, 2026, WHX LABS Bangkok 2026 (formerly Asia Health) was held at the Queen Sirikit National Convention Center (QSNCC), Bangkok, Thailand. The exhibition attracted more than 12,000 professional visitors and 400 exhibitors from 73 countries and regions, covering an exhibition area of 15,000 square meters, alongside 19 CME-accredited scientific conferences. Invited to participate, Encode Medical exhibited at Booth K28, showcasing its tuberculosis (TB) diagnostic solutions and products across multiple diagnostic technology platforms.
Comprehensive Mycobacteria Testing Solution
At the exhibition, Encode Medical presented its Comprehensive Mycobacteria Testing Solution, delivering a complete workflow from automated staining and microscopy, intelligent image interpretation, and specimen pretreatment to culture, drug susceptibility testing (DST), and minimum inhibitory concentration (MIC) determination.
The integrated solution combines six core instruments to support the three key functions of TB laboratories: microscopy, culture, and drug susceptibility testing. The workflow covers the following operational steps:
Automated Staining → Microscopy Screening → Intelligent Image Analysis → Sample Processing → Culture Isolation → MP64 Identification → Species Identification → Drug Susceptibility Testing → MIC Determination
Key features of the solution include:
Provides Minimum Inhibitory Concentration (MIC) data for multidrug-resistant tuberculosis (MDR-TB) management, helping differentiate resistance levels and supporting evidence-based treatment decisions.
Delivers drug susceptibility results within 7–10 days, covering 26 anti-tuberculosis drugs across 8 concentration gradients, while simultaneously generating resistance profiles for multiple drugs.
Supports a Direct Drug Susceptibility Testing (Direct DST) workflow, enabling completion of Mycobacterium tuberculosis culture and DST within 11 days.
Features a one-step pyrazinamide (PZA) susceptibility testing protocol, allowing shared media usage and a simplified operational process.
Supports susceptibility testing for newer anti-TB drugs, including Delamanid (DLM) and Bedaquiline (BDQ).
Microbiology, Molecular Biology, and Immunology Product Portfolio
In addition to its TB diagnostic solution, Encode Medical also showcased products from its three major technology platforms:
Microbiology
Bacterial culture, identification, and antimicrobial susceptibility testing products.
Suitable for routine pathogen detection and hospital infection surveillance.
Molecular Biology
PCR testing and nucleic acid extraction product lines.
Designed for pathogen gene detection and molecular typing applications.
Immunology
Colloidal gold, ELISA, and chemiluminescence assay products.
Applied to infectious disease antigen and antibody screening.
Exhibition Highlights
During the event, Booth K28 welcomed professional visitors from Thailand, Malaysia, Indonesia, the Middle East, Europe, and other regions.
On-site technical specialists introduced the equipment specifications, workflow design, and application scenarios of the mycobacteria testing solution. Visitors also engaged in technical discussions regarding laboratory implementation, instrument configurations, and the deployment of fully integrated automated workflows.
Looking Ahead
WHX LABS Bangkok represents one of Encode Medical’s strategic initiatives to strengthen product promotion and channel development across Southeast Asia.
Encode Medical stated that it will continue advancing product innovation and platform integration in the field of pathogenic microorganism diagnostics while enhancing localized technical support and service capabilities based on regional market needs. Through ongoing technology upgrades and channel expansion, the company aims to further extend its presence across ASEAN and global markets.
